Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 361

Results For "ED"

11247 News Found

Sukino Continuum appoints Sheshadri Vasan as President
People | May 20, 2026

Sukino Continuum appoints Sheshadri Vasan as President

Sheshadri brings with him extensive leadership experience spanning healthcare, diagnostics, telecom, and consumer goods industries


Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates
News | May 20, 2026

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform


Bayer’s stroke drug wins fast-track review in US
Drug Approval | May 20, 2026

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats


IGI’s new drug candidate ISB 2301 to target solid tumors
Biopharma | May 20, 2026

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027


NunaBio secures £6.5 million to scale DNA manufacturing platform
Biotech | May 19, 2026

NunaBio secures £6.5 million to scale DNA manufacturing platform

Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics


Pfizer promotes Ashish Doshi as Director at IITM RP, Chennai
People | May 19, 2026

Pfizer promotes Ashish Doshi as Director at IITM RP, Chennai

Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations


Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge
News | May 19, 2026

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels


SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer
Clinical Trials | May 19, 2026

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients


Alivus Life Sciences posts steady FY26 growth as margins surge past guidance
News | May 19, 2026

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26